StocksMedium•1 October 2026•
1 min read
Regeneron Drug Reduces Muscle Loss in Combination with Semaglutide
Key Facts
1A study indicated that a Regeneron drug reduces muscle loss when combined with Novo Nordisk's semaglutide.
A study indicated that a Regeneron experimental drug reduces muscle loss when combined with Novo Nordisk's semaglutide. Seeking Alpha reported that the combination therapy aims to improve the quality of weight loss by preserving lean muscle mass while reducing fat.
The clinical development addresses a common side effect of GLP-1 weight-loss treatments. This biotech advancement focuses on enhancing the long-term health outcomes for patients by ensuring that weight reduction primarily targets fat stores rather than vital muscle tissue.